Reuters logo
BRIEF-Tesaro reports Niraparib phase 3 ENGOT-OV16/NOVA trial secondary endpoint results
March 13, 2017 / 3:24 PM / 6 months ago

BRIEF-Tesaro reports Niraparib phase 3 ENGOT-OV16/NOVA trial secondary endpoint results

March 13 (Reuters) - Tesaro Inc

* Tesaro announces presentation of niraparib phase 3 ENGOT-OV16/NOVA trial secondary endpoint results during SGO

* Niraparib had no impact on efficacy of next-line therapy

* Niraparib significantly improved chemotherapy-free interval among patients who were germline brca mutation carriers

* PFS-2 data were statistically significant and favored Niraparib over control for patients in both gbrcamut cohort, non-gbrcamut cohort

* Progression-free surivival-2 and overall survival are immature, but favor Niraparib

* Among patients without Germline BRCA mutations, Niraparib arm successfully achieved statistical significance over control arm for secondary endpoint of CFI Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below